Mark H. O'Hara, MD

Articles by Mark H. O'Hara, MD

Favorable Results Seen With APX005M in Combination Therapy for Metastatic Ductal Pancreatic Adenocarcinoma

April 4th 2019

Cancer Network spoke with Mark H. O'Hara, MD, about the safety and efficacy of APX005M in combination with standard chemotherapy with or without nivolumab.

Latest Updated Articles

Favorable Results Seen With APX005M in Combination Therapy for Metastatic Ductal Pancreatic Adenocarcinoma
April 4th 2019

Trending on CancerNetwork

FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer

FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy

Daraxonrasib Shows Anti-Tumor Activity in Pretreated RAS+ Pancreatic Cancer

Zenocutuzumab Earns FDA National Priority Voucher in Cholangiocarcinoma

TIP125 ReDiscover-2, a Phase 3 Study of Zovegalisib (RLY-2608) + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-Mutant HR+/ HER2- Breast Cancer Following Recurrence or Progression on or After Treatment With a CDK4/6 Inhibitor (Trial in Progress)